The Readout Loud

369: Trump, Chinese biotech, and an industry career reshaped by illness

The Readout Loud

Show Notes

Listeners of this podcast probably know pharma consultant Mike Rea for his annual ranking of drug company R&D productivity. But this week, he penned a poignant personal essay explaining how some medical setbacks have impacted his professional life. He joins us to discuss.

But first, President Trump is considering a significant crackdown on drugs invented in China, according to a recent report in the New York Times. Industry support for the possible measures are mixed, however. While strengthening the U.S. biopharma industry garners wide support, so too does the freedom to source innovative drugs from Chinese biotechs.

More from The Readout Loud

Oct 23, 2026

Helen Branswell was a renowned infectious disease reporter who earned the respect and admiration of experts and public health officials with her authoritative, prescient reporting on the flu, polio, Ebola and the Covid-19 pandemic.

Oct 16, 2026

Longevity medicine is now estimated to be a multitrillion dollar industry. But what are people paying for, and does it work?

Oct 8, 2026

How has the National Institutes of Health been spending its budget? Why are biotech investors feeling gloomy? And what is the most quintessential Boston movie?

Oct 1, 2026

On this week’s episode of "The Readout LOUD": Why have so many Americans lost trust in science? And how have our policy leaders fueled that mistrust? We speak to STAT’s new trust-in-science reporter Nicholas Florko about the impact of Americans’ growing skepticism of science.

Sep 24, 2026

"The Readout LOUD" is going international this week.

See all episodes →